Sun Pharmaceutical Industries Ltd. reported net profit for the fiscal year ended March 31 of 26.65 billion Indian rupees, up 27.2% from 20.96 billion rupees a year earlier.
EPS for the Mumbai-based maker of generic drugs was 11.11 rupees for the year, up from 8.73 rupees a year ago. Total revenue from operations were 290.66 billion rupees, up from 264.89 billion rupees in the previous fiscal year.
For the fourth quarter ended March 31, reported net profit was 6.36 billion rupees, down from 13.43 billion rupees a year earlier. The fourth quarter of the previous year had the one-time impact of a distribution change for the company's India business, as well as a one-time benefit of 2.59 billion rupees.
EPS for the quarter was 2.65 rupees, down from 5.60 rupees in the year-ago period.
Total revenue from operations for the fourth quarter was 71.64 billion rupees, up from 69.77 billion rupees a year earlier.
As of May 27, US$1 was equivalent to 69.50 Indian rupees.